Oncology

The Disappointment of the NSABP C-08 Trial

September 16, 2009
Norman Wolmark

Norman Wolmark

Norman Wolmark on the study’s frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

    • Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with

  • Audio Journal of Oncology Breast Cancer Special 2005

    • Reporting from: - San Antonio Breast Cancer Symposium, December 8-11, 2004 - European Society for Medical Oncology Congress, October 29-November 10, 2004,

  • Breast Cancer: Further Support for Trastuzumab from Combined Analysis

    • Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials:

    Post a comment